期刊簡介 | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱![]() | Molecular Cancer LetPub Score 8.5
52 ratings
Rate
Reputation 8.6 Influence 8.3 Speed 8.7 | ||||||||||||||||||||||||
期刊簡稱 | MOL CANCER | ||||||||||||||||||||||||
ISSN | 1476-4598 | ||||||||||||||||||||||||
h-index | 103 | ||||||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||||||
自引率 (2023-2024) | 2.20%自引率趨勢 | ||||||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||||||
官方網站 | http://molecular-cancer.biomedcentral.com | ||||||||||||||||||||||||
在線稿件提交 | https://submission.nature.com/new-submission/12943/3 | ||||||||||||||||||||||||
開放訪問 | Yes | ||||||||||||||||||||||||
出版商 | BioMed Central | ||||||||||||||||||||||||
主題領域 | 医学 | ||||||||||||||||||||||||
出版國/地區 | ENGLAND | ||||||||||||||||||||||||
發行頻率 | 月刊 | ||||||||||||||||||||||||
創刊年 | 2002 | ||||||||||||||||||||||||
每年文章數 | 165每年文章數趨勢 | ||||||||||||||||||||||||
黃金OA百分比 | 100.00% | ||||||||||||||||||||||||
OA Related Info![]() | APC: Yes( EUR3990; USD4890; GBP3490; ) APC waiver:Check Notes Other charges: No Keywords: oncology、tumour biology、cancer antigens Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | ||||||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1476-4598%5BISSN%5D | ||||||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Average 2 Month(s) | ||||||||||||||||||||||||
競爭力 * | 來自作者的數據: About 50% | ||||||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
|
首頁 上一頁 2 3 4 5 6 7 8 下一頁 末頁 (頁 | |
[Molecular Cancer] 的評論 | 撰寫評論 |
作者: 重阳悦爱 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-29 12:56:35 評論於 Review speed: 3.0 | Submission acceptance rate: 25.0 Focus areas: Oncology Experience sharing: The journal has started to request original data. To be objective, Molecular Cancer currently has a high rejection rate. Let's give it a try and submit an article now ![]() ![]() |
作者: 蒙德青文 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-23 08:33:52 評論於 What is the status of the submission, will there be an email notification? ![]() ![]() |
作者: 凌霄迎波 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-22 18:49:02 評論於 The submission on June 20th was incorrect ![]() ![]() |
作者: 凌霄迎波 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-15 13:52:50 評論於 It was reviewed in just one day ![]() ![]() |
作者: Nick Peacock 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-13 19:43:54 評論於 Research Focus: Immunology; Tumor; Gene Experience Sharing: Submitted for review on August 14th ![]() ![]() |
作者: 景焕小姐姐 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-12 18:57:10 評論於 Excuse me, do you have any plans behind you? ![]() ![]() |
作者: 景焕小姐姐 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-11 22:28:22 評論於 How many days after the editor is assigned will it be reviewed? ![]() ![]() |
作者: 景焕小姐姐 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-11 22:26:32 評論於 How is your current status? How long until the second trial? ![]() ![]() |
作者: 景焕小姐姐 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-11 22:22:05 評論於 Any progress? ![]() ![]() |
作者: 景焕小姐姐 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-11 13:38:21 評論於 Review speed: 6.0 Research focus: Tumor experience sharing Question for all the comrades who have submitted their manuscripts: How long does it usually take for the editor to make the next decision after being appointed? It has been 4 days now ![]() ![]() |
作者: 景焕小姐姐 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-11 11:01:05 評論於 May I ask when you will submit the draft in the next few days? ![]() ![]() |
作者: 魔都吉星 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-10 22:56:37 評論於 It hasn't been a month yet, right? What's the situation now? ![]() ![]() |
作者: 凌霄迎波 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-05 22:22:24 評論於 Review speed: 3.0 Experience sharing: Submitted on July 20th, still no updates today, it's been almost two months. Any fellow peers in the same situation? When can we expect revisions? ![]() ![]() |
作者: 碧波妙蝶 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-05 10:36:51 評論於 Have you made progress to the next step? It's been over two weeks since I submitted my article and still no editor appointed ![]() ![]() |
作者: 凌霄迎波 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-07-31 11:12:39 評論於 Review speed: 2.0 Research emphasis: circRNA Tumor experience sharing: Submitted on July 20th, there has been no change today. Are there any buddies in the same situation? When can I revise it? ![]() ![]() |
作者: 天神院梦凝 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-07-27 08:29:47 評論於 Looking at the entire development process of IF, this journal is the classic 5-point magazine (=JBC? Not necessarily). For whatever reason, putting low-quality articles or even fake articles in it, this journal cannot be a top journal. Just like the elementary school textbook problem: if there are 10 birds on a tree, and you knock down one with a potato, how many are left? The Impact Factor says there are 9 left, but the professionals have already left ![]() ![]() |
作者: 凌霄迎波 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-06-27 19:55:52 評論於 What does peer review mean? Does it mean that it has been sent for review? ![]() ![]() |
作者: 蒙德青文 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-06-14 13:33:21 評論於 Review speed: 1.0 | Submission acceptance rate: 25.0 Weighted research direction: Oncology Experience sharing: Rejected in three days, asked for a revision as a correspondence. Forget it ![]() ![]() |
作者: 重庆医科大学基础 領域: 医学 審稿時間: 3.0 month(s) 結果: 修改後接受 撰寫評論 |
2023-04-20 23:13:20 評論於 This journal was included in the warning list by our school before the new year and is not recognized. Four articles were submitted by colleagues in our department, and all of them were accepted. The proportion of Chinese authors is very high, and it is indeed of relatively low quality. It was a waste of time. ![]() ![]() |
作者: 淡忘 領域: 医学 審稿時間: 1.0 month(s) 結果: 修改後接受 撰寫評論 |
2023-04-03 20:20:56 評論於 The impact factor has increased, and it seems a bit difficult for Chinese people to publish articles. Finally, I got one this year. ![]() ![]() |
作者: 天心来了 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-03-19 20:47:57 評論於 Review speed: 6.0 | Submission acceptance rate: 50.0 Research focus: Tumor microenvironment Experience sharing: I submitted a review article in December 2022, received major revisions over Chinese New Year, had two weeks to make revisions, added three tables, and made many changes. After a second round of review, two reviewers had no comments, except one suggested changing the title. The article was accepted in mid-March 2023. Overall, the process went smoothly and I consider myself lucky to have my first article accepted as a master's student ![]() ![]() |
作者: 天心来了 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-03-19 16:02:57 評論於 I passed my second exam in three weeks ![]() ![]() |
作者: Vito Minnie 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-03-12 13:50:24 評論於 I have also read this article, it lacks novelty and depth of research, it is too shallow, just barely reaching a 5-point level, a clichéd ceRNA mechanism ![]() ![]() |
作者: 魔都小柔 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-02-13 23:51:53 評論於 molecular cancer, the shrine of frozen time, one year has passed, can't hold onto the spring and autumn, living up to the years and not letting you down ![]() ![]() |
作者: 魔都小柔 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-02-13 17:12:16 評論於 First must be the paper, followed by the carrot and then the stick ![]() ![]() |
首頁 上一頁 2 3 4 5 6 7 8 下一頁 末頁 (頁 |
Contact us